OPG/RANK/RANKL axis in atrial fibrillation

Cardiology (Switzerland)

Volumn 125, Issue 3, 2013, Pages 174-175

  Xi, Lei ^a   Cao, Hailong ^b   Chen, Yijiang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BIOLOGICAL MARKER; TISSUE INHIBITOR OF METALLOPROTEINASE;

ACUTE CORONARY SYNDROME; BLOOD VESSEL CALCIFICATION; DENDRITIC CELL; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; LETTER; MACROPHAGE; MONOCYTE; MORTALITY; OSTEOBLAST; OSTEOCLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; VASCULAR BIOLOGY; EXPERIMENTAL RAT; HEART FAILURE; HEART FUNCTION; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ATRIAL FIBRILLATION; HEART ATRIA; HUMANS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84878744718     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000351441     Document Type: Letter

References (13)

1. Yamaguchi K, Kinosaki M, Goto M, et al: Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998; 273:5117-5123. (Pubitemid 28108672)
2. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: The roles of osteo-protegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15:2-12. (Pubitemid 30026926)
3. Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, et al: Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cyto-chem 2004; 52:821-831. (Pubitemid 38703137)
4. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al: Osteoproteger-in is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-14367. (Pubitemid 28319153)
5. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC: Increased osteo-protegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88:1024-1028. (Pubitemid 36337751)
6. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, et al: Dysregulated osteoprote-gerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111:2461-2468. (Pubitemid 40696134)
7. Venuraju SM, Yerramasu A, Corder R, Lahiri A: Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55: 2049-2061.
8. Xu J, Cui G, Esmailian F, et al: Atrial extracel-lular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004; 109: 363-368. (Pubitemid 38133905)
9. Yan AT, Yan RT, Spinale FG, Afzal R, Guna-singhe HR, Stroud RE, et al: Relationships be-tween plasma levels of matrix metalloprotein-ases and neurohormonal profile in patients with heart failure. Eur J Heart Fail 2008; 10: 125-128.
10. Feng W, Li W, Liu W, Wang F, Li Y, Yan W: IL-17 induces myocardial fibrosis and en-hances RANKL/OPG and MMP/TIMP sig-naling in isoproterenol- induced heart failure. Exp Mol Pathol 2009; 87:212-218.
11. Jono S, Ikari Y, Shioi A, et al: Serum osteopro-tegerin levels are associated with the presence and severity of coronary artery disease. Circu-lation 2002; 106:1192-1194. (Pubitemid 34988634)
12. Hofbauer LC, Schoppet M: Clinical implica-tions of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292:490-495. (Pubitemid 38988958)
13. Pedersen ER, Ueland T, Seifert R, et al: Serum osteoprotegerin levels and long-term progno-sis in patients with stable angina pectoris. Atherosclerosis 2010; 212:644-649.